Iovance Biotherapeutics, Inc. (0JDK.L) LSE

4.02

-0.02000002(-0.50%)

Updated at June 02 05:50PM

Currency In USD

Key Executives

Name	Title	Pay	Year Born
Frederick G. Vogt	Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director	1.13M	1974
Elma S. Hawkins	Advisor to the Board	465,395	1957
Corleen Roche	Chief Financial Officer	494,150	1966
Igor Bilinsky	Chief Operating Officer	738,374	1973
Friedrich Graf Finckenstein	Chief Medical Officer	764,634	1967
Daniel G. Kirby	Chief Commercial Officer	804,031	1972
Raj K. Puri	Chief Regulatory Officer	867,158	1956
Sara Pellegrino	Senior Vice President of Investor Relations & Corporate Communications	0	N/A
Tracy Winton	Executive Vice President of Human Resources	0	N/A
Marc R. Theoret	Senior Vice President of Regulatory Strategy	0	N/A
Brian Shew	Senior Vice President & Head of Digital and Information Technology	0	N/A
Matthew W. Rosinack	Principal Accounting Officer	0	1972
Howard Johnson	Chief Business Officer	0	1960
Kevin Smyth	Executive Vice President of Quality	0	N/A

Name

Title

Pay

Year Born

Frederick G. Vogt

Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director

1.13M

1974

Elma S. Hawkins

Advisor to the Board

465,395

1957

Corleen Roche

Chief Financial Officer

494,150

1966

Igor Bilinsky

Chief Operating Officer

738,374

1973

Friedrich Graf Finckenstein

Chief Medical Officer

764,634

1967

Daniel G. Kirby

Chief Commercial Officer

804,031

1972

Raj K. Puri

Chief Regulatory Officer

867,158

1956

Sara Pellegrino

Senior Vice President of Investor Relations & Corporate Communications

N/A

Tracy Winton

Executive Vice President of Human Resources

N/A

Marc R. Theoret

Senior Vice President of Regulatory Strategy

N/A

Brian Shew

Senior Vice President & Head of Digital and Information Technology

N/A

Matthew W. Rosinack

Principal Accounting Officer

1972

Howard Johnson

Chief Business Officer

1960

Kevin Smyth

Executive Vice President of Quality

N/A

Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.